Teva announces recruitment completion of Phase III clinical Study of mdc-TJK/Olanzapine LAI

Published: 10-Jan-2024
Research & Development

Teva Pharmaceutical Industries announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase III clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference

Results of the study are expected in the second half of 2024. mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the
treatment of schizophrenia.

It has the potential to be the first long-acting olanzapine with a favorable safety profile. Teva remains fully responsible to lead the development and commercialisation of olanzapine LAI globally.

MedinCell may receive up to $117m in development and commercial milestones during the coming years for mdc-TJK, and is eligible for royalties on all net sales.

  • Companies:
  • Teva
  • MedinCell
See more

You may also like

Research & Development

Teva & Medincell release Phase III SOLARIS trial results for olanzapine in schizophrenic adults

Read more
The results indicate that Medincell's TEV-'749 subcutaneous extended release device for the administration of olanzapine in schizophrenic adults met primary and secondary endpoints

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are sterile preparations that are administrated directly into the systemic circulation of humans or animals

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Teva & Medincell release Phase III SOLARIS trial results for olanzapine in schizophrenic adults

The results indicate that Medincell's TEV-'749 subcutaneous extended release device for the administration of olanzapine in schizophrenic adults met primary and secondary endpoints
Research & Development

Teva UK and Closed Loop Medicine partner to advance personalised medicine development

SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Research & Development

Sanofi and Teva's collaboration to deliver inflammatory bowel disease treatment

TEV’574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease by Sanofi and Teva Pharmaceuticals
Research & Development

Teva completes facilities purchase in Pennsylvania

Investment will see the Israeli drug-maker set up a Research & Development campus in the US
Research & Development

Teva buys rights to develop small-molecule CGRP antagonists

Enters into agreement with Heptares to develop novel products for the treatment of migraine
Regulatory

Asthma – reslizumab

Acute asthma attacks can require hospitalisation or even prove fatal, but in some sufferers the standard regimen does not give adequate control
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
Subscribe now